Clinical Trials Logo

Clinical Trial Summary

Acute myocardial infarction is a major cause of mortality and morbidity. Primary percutaneous coronary intervention (pPCI) is currently the most effective treatment strategy in acute myocardial infarction. However, a sizable number of patients fail to restore optimal myocardial reperfusion, mostly because of the 'no-reflow' phenomenon. Melatonin is the chief indoleamine produced by the pineal gland, and a well-known antioxidant and free radical scavenger. Several studies have shown that melatonin protects against ischemia/reperfusion injury (IRI). In our previous study, melatonin markedly reduced infarcted area, improved cardiac function and reduced lactate dehydrogenase release in rats. The investigators planned to research the cardioprotective effects of intravenous melatonin administered prior to reperfusion and continued after restoration of coronary blood flow in patients with ST segment elevation myocardial infarction undergoing pPCI.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03303378
Study type Interventional
Source Chinese PLA General Hospital
Contact wei ren chen, M.D.
Phone +8610-66876231
Email chen_weiren@sina.com
Status Recruiting
Phase N/A
Start date November 1, 2017
Completion date November 1, 2019

See also
  Status Clinical Trial Phase
Not yet recruiting NCT03591991 - Empagliflozin on Cardiac-renal Injury in Patients With STEAMI Patients After Primary PCI N/A
Recruiting NCT06128993 - Trans-coronary Cooling and Dilution for Cardioprotection During Revascularisation for ST-elevation Myocardial Infarction N/A
Completed NCT03500783 - Nitric Oxide-mediated Cardioprotection During Cardiac Surgery With Cardiopulmonary Bypass Phase 1/Phase 2
Recruiting NCT03939338 - Combination With Treg Levels and CMR to Assess the Severity and Prognosis of Reperfusion Injury After PPCI in STEMI Patients
Enrolling by invitation NCT05734612 - The Role of Colchicine in Reducing The Rate of Myocardial Reperfusion Injury Phase 3
Completed NCT05215743 - Combined Antioxidant Therapy Against Myocardial Reperfusion Injury. Phase I Study. Phase 1